SCHEMBL25768039

SCHEMBL25768039

CO[C@@H]1OC(CO)[C@@H](O)[C@H](O[C@@H]2OC(C(=O)O)[C@@H](C)[C@H](O)C2O)C1NC(C)=O

nearest known ligand 0.49

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ LGALS3 P17931 7/20 0.49
▸ LGALS7; LGALS7B P47929 2/20 0.47
▸ LGALS1 P09382 1/20 0.47
▸ LGALS8 O00214 3/20 0.46
▸ LGALS4 P56470 1/20 0.46
▸ LGALS9 O00182 2/20 0.46
▸ MAPK1 P28482 2/20 0.44
▸ CD69 Q07108 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.42
▸ THRB P10828 1/20 0.42
▸ PTN P21246 1/20 0.41
▸ MDK P21741 1/20 0.41
▸ BDNF P23560 1/20 0.41
▸ CHIA Q9BZP6 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11965622 1.00 LGALS3 (0.49) LGALS3LGALS7; LGALS7BLGALS1LGALS8LGALS4
SCHEMBL17899826 0.90 BDNF (0.41) LGALS3LGALS7; LGALS7BLGALS1LGALS8LGALS4
Dermatan SCHEMBL19184706 0.90 LGALS3 (0.49) LGALS3LGALS7; LGALS7BLGALS1LGALS8LGALS4
Dermatan SCHEMBL19846466 0.90 LGALS3 (0.49) LGALS3LGALS7; LGALS7BLGALS1LGALS8LGALS4
Dermatan SCHEMBL12691925 0.90 LGALS3 (0.49) LGALS3LGALS7; LGALS7BLGALS1LGALS8LGALS4
Dermatan SCHEMBL29360360 0.90 LGALS3 (0.49) LGALS3LGALS7; LGALS7BLGALS1LGALS8LGALS4
Dermatan SCHEMBL16311126 0.90 LGALS3 (0.49) LGALS3LGALS7; LGALS7BLGALS1LGALS8LGALS4
Dermatan SCHEMBL13472480 0.90 LGALS3 (0.49) LGALS3LGALS7; LGALS7BLGALS1LGALS8LGALS4
Dermatan SCHEMBL18232151 0.90 LGALS3 (0.49) LGALS3LGALS7; LGALS7BLGALS1LGALS8LGALS4
SCHEMBL19675783 0.89 MAPK1 (0.57) LGALS3LGALS7; LGALS7BLGALS1LGALS8LGALS4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11780970-B2 Carbohydrate crosslinker GALDERMA HOLDING S.A. (CH) 2023-10-10 — — US disclosed
US-20230212360-A1 CARBOHYDRATE CROSSLINKER Galderma Holding SA (CH) 2023-07-06 — — US disclosed
US-11643509-B2 Carbohydrate crosslinker Galderma Holding SA (CH) 2023-05-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11780970-B2 Carbohydrate crosslinker CD44, CSGALNACT1, STT3B LGALS3 78/4885LGALS7; LGALS7B 309/4885LGALS1 122/4885
US-11643509-B2 Carbohydrate crosslinker CD44, CSGALNACT1, STT3B LGALS3 78/4885LGALS7; LGALS7B 309/4885LGALS1 122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback